Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Investor Presentation (April 2025)
35 slides from Lumos Diagnostics's investor presentation, Apr 2, 2025
Slide 1: ASX Announcement: Investor Presentation - Information Session in Sydney
ASX ANNOUNCEMENT Investor Presentation - Information Session in Sydney on 2 April 2025 MELBOURNE, Australia (2 April 2025) – Lumos Diagnostics Holdings Ltd (ASX: LDX, “Lumos” or the For personal use only “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to provide a cop
Slide 2: Media and Investor Contacts
Media Contact: Haley Chartres – Australia H^CK Director haley@hck.digital +61 423 139 163 Investor Contact: Jane Lowe Managing Director, IR Department ir@lumosdiagnostics.com +61 411 117 774 Company Registered Office: For personal use only Lumos Diagnostics Holdings Ltd Level 4, 100 Albert Rd South
Slide 3: Lumos Diagnostics Holdings Limited Investor Overview
For personal use only Lumos Diagnostics Holdings Limited Investor Overview 2 April 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics™. All rights reserved. 1
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of (Company). achiev
Slide 5: Company Overview and Key 1H FY25 Highlights
For personal use only Company Overview and Key 1H FY25 Highlights
Slide 6: Who is Lumos and why do we exist?
Lumos develops, manufactures For personal use only Who is Lumos and distributes innovative and why diagnostic products do we exist? – delivering actionable information, in real time, at the point-of-care. Improve the practice of medicine. © Lumos Diagnostics™, all rights reserved 4
Slide 7: Company Overview
Company Overview Experienced leadership team For personal use only Comprehensive & integrated offering from product concept design through to manufacture and distribution Developed and launched one of kind proprietary point-of-care diagnostic products - FebriDx Transformational development agreement
Slide 8: Lumos Business Overview
Lumos Business Overview For personal use only Lumos offers end-to-end point of care (POC) diagnostic test PRODUCTS COMMERCIAL SERVICES development, from initial assay creation to high-volume manufacturing. We develop FebriDx & Women’s Development Contract and sell our own tests and also ViraDx Healt
Slide 9: Key Highlights from 1H FY25
Key Highlights from 1H FY251 For personal use only Revenue of $6.3 million for the half-year, up Product revenue was up 227% and Services Adjusted EBITDA loss of $0.9 million, and 128% compared to PCP (1H FY24 - $2.8 million) revenue was up 118%. Gross Profit margin was improvement of 77% over the l
Slide 10: Products Division
For personal use only Products Division
Slide 11: Product Portfolio Approach
Product Portfolio Approach For personal use only Be a leader in point-of-care testing Focus on verticals with existing Leverage broad partnering strategy with innovative products, offering markets / reimbursement / transition for distribution and sales, secure a portfolio of assays for visual read f
Slide 12: FebriDx: A Simple and Unique Test for Microbial Infection
FebriDx® A Simple And Unique Test For Microbial Infection FebriDx® can rapidly identify patients who have a microbial infection1 and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes For personal use only FebriDx® Test Procedure and Interpretation
Slide 13: FebriDx Addresses a Major Need: Antibiotic Overprescription
FebriDx® Addresses a major need: Antibiotic Overprescription For personal use only ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE ANTIBIOTICS PRESCRIBED Common cold Sinusitis Other infections Bronchitis Sore throat Ear infection 211M 44% 40% 58 prescribed % Antibiotic prescriptions Of antibiotic prescri
Slide 14: Potential Benefits of FebriDx
Potential Benefits of FebriDx® FebriDx® can deliver significant tangible benefits to participants across the health system For personal use only Patients Physicians Insurers and Government • Reduce incidence of side effects • Greater confidence on treatment • Reduce antimicrobial resistance (AMR) ca
Slide 15: FebriDx CLIA Waiver Update
FebriDx® CLIA Waiver Update BARDA partnership agreement | October 2024 For personal use only To support CLIA waiver and pediatric studies: non-dilutive funding up to US$8.3m • US$3.0m to support CLIA waiver study • US$5.3m to support pediatric study (children under 12yrs old) • Payments based on ach
Slide 16: ViraDx: Point-of-Care test for key respiratory infections
ViraDx™ Point-of-Care test for key respiratory infections For personal use only ViraDx highly relevant POC test for post-pandemic environment • SARS-CoV-2 pandemic increased consumer and healthcare point-of-care testing • ViraDx is a 3-in-1 test for COVID-19/Flu A/Flu B ViraDx market update Sales Co
Slide 17: Lumos Future Products: Women's Sexual Health
Lumos Future Products Women’s Sexual Health - $10B For personal use only 1-2 DAYS Prevalence Clinical Need POC Diagnostic Need Affects 30%-40% of women globally. Multiple infectious organisms. Rapid & accurate testing on site needed. >10M heath care visits annually in the Similar symptoms / hard to
Slide 18: Women's Sexual Health – Current Diagnostic Practices
Women’s Sexual Health – Current Diagnostic Practices IN CLINIC TESTING EXTERNAL LAB TESTING For personal use only Physical Exam Microscopic Exam Pathogen Testing Pathogen Testing 1-5 DAYS Practice Current Physical exam alone is not Microscopy assists in identifying Pathogen Testing today requires ex
Slide 19: Women's Sexual Health – The Opportunity
Women’s Sexual Health – The Opportunity IN CLINIC TESTING EXTERNAL LAB TESTING For personal use only Physical Exam Microscopic Exam Pathogen Testing Pathogen Testing 1-5 DAYS Practice Current Majority of clinics do not have in Instead, clinics send out testing to Lumos Women’s Sexual Health POC test
Slide 20: Lumos Product Roadmap | Women's Sexual Health
Lumos Product Roadmap | Women’s Sexual Health CURRENT - DISTRIBUTION FUTURE - LUMOS POC PRODUCTS For personal use only Revenue & Market Learning Pathogen Detection | Visual & Reader Interpretation URGENT CARE GYN CLINIC & Lumos – As a Distributer Lumos Products – Visual Read Lumos Products on Lumos
Slide 21: Commercial Services Division
For personal use only Commercial Services Division © Lumos Diagnostics™. All rights reserved. 19
Slide 22: Commercial Services Capabilities
Commercial Services Capabilities Lumos offers the full range of in-house expertise required to deliver a complete, commercially ready solution. For personal use only DEVELOPMENT & MANUFACTURING PLATFORM TECHNOLOGIES ASSAY READERS EMR & CONNECTIVITIY © Lumos Diagnostics™. All rights reserved. 20
Slide 23: How we add value to partners
How we add value to partners We work with partners through the whole diagnostic product development cycle, then provide support once their products are in market. For personal use only Customer launch and support Manufacture Clinical studies Verification and validation of requirements Conduct feasib
Slide 24: Hologic - Strategic Partnership
Hologic - Strategic Partnership Fetal Fibronectin (fFN)1 For personal use only Historic relationship with Lumos <> Hologic – fFN is a biomarker indicating a heightened risk working together at multiple levels of pre-term delivery and is the largest segment of the pre-term birth diagnostic kit market
Slide 25: Hologic - fFN Product development overview and opportunity
Hologic - fFN Product development overview and opportunity For personal use only Current test: Next generation test Hologic – the opportunity ahead Rapid fFN TLiQ concept (mock-up) Verification Clinical and validation study Manufacturing Second test development and IP © Lumos Diagnostics™. All right
Slide 26: Key Priorities
For personal use only Key Priorities © Lumos Diagnostics™. All rights reserved. 24
Slide 27: Key Priorities
Key Priorities For personal use only Implement bacterial FDA pre-submission for Continue to drive FebriDx Deliver on Hologic fFN Progress to formal product positive enrichment FebriDx pediatric study product awareness and development milestones - development on the first strategy for FebriDx CLIA in
Slide 28: Appendix – Other Information
For personal use only Appendix – Other Information
Slide 29: Board of Directors
Board of Directors For personal use only Sam Lanyon Bronwyn Le Grice Lawrence Mehren Catherine Robson Doug Ward Non-Executive Chair Non-Executive Director Non-Executive Director Non-Executive Director Managing Director & CEO © Lumos Diagnostics™. All rights reserved. 27
Slide 30: Highly Experienced Leadership Team
Highly Experienced Leadership Team For personal use only Doug Ward Barrie Lambert Sacha Dopheide, PhD Paul Kase CEO & Managing Director Chief Financial Officer Chief Technology Officer SVP of Commercial Operations Doug Ward has more than 30 years of biotech Barrie Lambert has more than 25 years of S
Slide 31: Company Snapshot
Company Snapshot Issued Capital Share Price & Volume For personal use only Shares 748.5m Volume Price Options 157.4m 0.07 50 Market Capitalization (AUD) 0.06 40 Share Price ($) 0.05 Volume (m) Share price1 A$0.023 0.04 30 Market value A$17.2m 0.03 20 0.02 Pro-forma Cash (31 Dec 2024 – in AUD) A$8.7m
Slide 32: Profit & Loss Summary – 1H FY25
Profit & Loss Summary – 1H FY25 Strong revenue growth and EBITDA improvement For personal use only Six months ended 31 Dec 1H FY25 1H FY24 % Change Revenue • Total revenue $6.3m (+128%) Services revenue 5,468 2,510 +118% • Services revenue $5.5m (+118%) - Positive impact from Hologic Products revenu
Slide 33: Balance Sheet Summary – 1H FY25
Balance Sheet Summary – 1H FY25 Improved net asset position For personal use only Period ending 31 Dec 2024 30 Jun 2024 +/- Assets • Inventory mainly raw materials for ViraDx ahead of US flu Cash 5,532 6,479 -947 season Inventories 1,346 784 +562 • Trade & Other Receivables includes BARDA receivable
Slide 34: Cashflow Summary – 1H FY25
Cashflow Summary – 1H FY25 Closing cash $5.5m - well supported capital raise • Receipts from customers at $3.0m, is lower than revenue reported For personal use only Six months ended 31 Dec 1H FY25 1H FY24 +/- mainly due to recognising revenue on Hologic IP agreement (cash Receipts from customers 3,
Slide 35: For personal use only
For personal use only www.lumosdiagnostics.com © Lumos Diagnostics™. All rights reserved. 33
Lumos Diagnostics Holdings — Investor Presentation (April 2025) on 6ix